主 办:北 京 中 医 药 大 学
ISSN 1006-2157 CN 11-3574/R

北京中医药大学学报 ›› 2017, Vol. 40 ›› Issue (4): 344-349.doi: 10.3969/j.issn.1006-2157.2017.04.015

• 临床研究 • 上一篇    下一篇

治疗冠心病方剂用药规律的数据挖掘研究*

钟小雪1,2, 何庆勇1#, 尹湘君1,2, 赵桂芳1,2   

  1. 1 中国中医科学院广安门医院 北京 100053;
    2 北京中医药大学
  • 收稿日期:2016-06-13 出版日期:2017-04-30 发布日期:2017-04-30
  • 通讯作者: 何庆勇,男,博士,副主任医师,副教授,E-mail:zxxbjzyydx414@126.com
  • 作者简介:钟小雪,女,在读硕士生
  • 基金资助:
    *国家自然科学基金资助项目(No.81202803),中央公益性科研院所基本科研业务费专项资金项目(No.ZZ0908023)

Data mining of medicinal combination from Chinese medicine formula for coronary heart disease*

ZHONG Xiaoxue1,2, HE Qingyong1#, YIN Xiangjun1,2, ZHAO Guifang1,2   

  1. 1 Guang’anmen Hospital, China Academy of Chinese Medical Sciences;
    2 Beijing University of Chinese Medicine,Beijing 100029
  • Received:2016-06-13 Online:2017-04-30 Published:2017-04-30

摘要: 目的 对治疗冠心病中药复方进行数据挖掘,研究其方剂用药规律。希望对临床研发冠心病中药新药有所裨益。方法 提取1985年9月至2015年7月国家专利数据库中治疗冠心病的263项中药复方专利并建立数据库,运用中医传承辅助系统软件(V2.5),采用关联规则、复杂网络、熵方法分析等技术挖掘中药复方的方剂用药规律。结果 提取出治疗冠心病的263项中药复方专利中,最多有30味药,最少1味药,平均(6.20±6.10)味药。最常见的治则为活血化瘀(87次,33.08%);最常见的单药为丹参(143次,54.40%)等;最常见的对药为丹参-川芎(62次,23.57%)等;最常见的角药为丹参-川芎-红花(33次,12.55%)等。基于关联规则发现常见药物组合有:桃仁→红花(置信度0.844),降香→丹参(置信度0.794),红花+赤芍→川芎(置信度1), 川芎+桃仁→红花(置信度0.952)。基于复杂网络发现的核心药物有:丹参、三七、红花、当归、川芎、甘草、黄芪、麦冬;通过熵方法提取出的新方组合有:木香、苏合香、安息香、樟脑、薄荷、高良姜、白芍、陈皮、鸡内金、北沙参。结论 本研究揭示了治疗冠心病的中药复方专利的核心用药和方剂用药规律,为临床用药提供指导。

关键词: 冠心病, 专利, 关联规则, 复杂网络, 熵方法, 用药规律, 新药研发

Abstract: Objective To explore the law of medicinal combinationin traditional Chinese medicine for coronary heart disease using data mining method in order to provide reference for research and development of new drug.Methods This study built a new database based on 263 compound Chinese medicine formulas for coronary heart disease, which were selected from the National Patent Database from September 1985 to July 2015. Association rules, complex network analysis and entropy method were applied to explore the combination law of traditional Chinese compound formula using the traditional Chinese medicine inheritance system software (V2.5). Results Among the selected 263 compound formulas, the most complex one consisted of 30 herbs; the simplest,only one herb; with an average of 6.20±6.10 herbs in one formula.Activating blood and resolving stasis was the most common therapeutic principle(87 cases, 33.08%).Radix et Rhizoma Salviae Miltiorrhizae (Danshen root, Danshen) was the most frequently used herb(143 cases,54.40%); the combination of Danshen and Rhizoma Chuanxiong (Chuanxiong Rhizome, Chuanxiong), and Danshen,Chuanxiong, and Flos Carthami(Safflower, Honghua), were the most frequent couple and triple combination respectively (62, 23.57% and 33, 12.55%); Based on the association rules, frequent medicinal combination were Semen Persicae(Peach Kernel, Taoren)→Honghua(CC=0.844); Lignum Dalbergiae Odoriferae(Rosewood,Jiangxiang)→Danshen(CC=0.84); Honghua, Radix Paeoniae Rubra (red peony root,Chishao) →Chuanxiong(CC=1);Chuanxiong, Taoren→Honghua(CC=0.952). Based on complex network analysis,the core medicinals identified were Radix et Rhizoma Notoginseng(Pseudoginseng Root, Sanqi), Danshen, Honghua, Radix Angelicae Sinensis(Chinese Angelica,Danggui), Chuanxiong, Radix Astragali(Astragalus Root,Huangqi), Radix et Rhizoma Glycyrrhizae(Licorice Root, Gancao), and Radix Ophiopogonis(Dwarf Lilyturf Tube, Maidong). The new compound extracted by entropy method involved Radix Aucklandiae(Common Aucklandia Root,Muxiang), Styrax(Storax, Suhexiang) Benzoinum (Benzoin, Anxixiang), Camphora (Camphor, Zhangnao), Herba Menthae(Field Mint,Bohe), Rhizoma Alpiniae Officinarum (Galangal,Gaoliangjiang), Radix Paeoniae Alba (Galangal White Peony Root,Baishao), Pericarpium Citri Reticulatae (Citrus,Chenpi)Endothelium Corneum Gigeriae Galli (Chicken Gizzard Lining,Jineijin), and Radix Glehniae (Straight Ladybell Root,Beishashen).Conclusion This study sheds light on the combination law of Chinese medicine for coronary heart disease, and provides reference for clinical practice.

Key words: coronary heart disease, patent, association rules, complex networks, entropy method, combination rule, research and development of new drug

中图分类号: 

  • R259.44